The Rising Pressure of AMR in Aquaculture

As aquaculture continues to scale to meet growing global protein demand, the industry faces a complex balancing act: maintaining fish health while reducing reliance on antibiotics. Historically, antibiotics have played a role in managing bacterial outbreaks in species like Atlantic salmon, but their use has contributed to the broader global concern around resistance.

Pathogens in groups such as Aeromonas, Vibrio, and Flavobacterium are not new to aquaculture. What is changing is how they respond to treatment. Increasingly, producers are encountering reduced efficacy of traditional therapeutics, making disease events harder to control, more costly, and more unpredictable.

The implications of antimicrobial resistance (AMR) in aquaculture extend far beyond individual farms, creating ripple effects across the entire industry. With treatment options becoming less effective, greater volatility for producers can be expected; particularly around mass mortality events caused by acute disease outbreaks. At the same time, regulatory scrutiny continues to intensify around antibiotic use, with buyers and consumers placing increasing emphasis on responsibly farmed, sustainable seafood.

There is growing alignment between regulators, researchers, and producers around a shared goal: reduce antibiotic dependence without compromising performance.

The industry is responding with a clear pivot, from treatment to prevention.

Functional feeds, vaccines, improved husbandry, and other, “alternative” treatments, are all part of the solution set. Ingredients with inherent antimicrobial or immune-supporting properties are gaining traction as tools to enhance resilience before disease takes hold. This conversation is becoming more geographically specific, as support strategies aim to target the pathogen profiles of specific sites, farms, or regions.

But innovation alone isn’t enough. These solutions must be rigorously tested, validated, and aligned with regulatory expectations before they can be confidently adopted at scale. This is where robust laboratory and applied research capabilities become essential.

Understanding whether a product truly reduces pathogen load, enhances immune response, or improves survival under challenge conditions requires more than anecdotal evidence. It demands controlled, repeatable, and scientifically sound testing.

At Onda, our LabTech services are designed to bridge the gap between early-stage concepts and commercial reality. Using a combination of in-vitro and in-vivo models, we support clients in evaluating antimicrobial activity against key aquaculture pathogens, characterizing mechanisms of action such as immune modulation and microbiome interactions, and generating robust data to support regulatory submissions and product claims. This approach helps de-risk product development before advancing to large-scale trials, enabling innovators to move forward with confidence while providing producers and regulators assurance that new solutions are both effective and responsibly validated.

AMR is not a challenge that can be solved by a single innovation or intervention, but rather requires a coordinated approach grounded in science, transparency, and continuous improvement. The path forward is clear: invest in prevention, rigorously validate innovation, and ensure that every new solution is supported by credible, high-quality data. In an environment where treatment options are narrowing, the ability to prove performance before problems arise has never been more critical.